Intracerebral Hemorrhage

8
Pipeline Programs
9
Companies
10
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
6
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
2
Recombinant Activated Factor VIIPhase 31 trial
Recombinant Factor VIIaPhase 31 trial
Active Trials
NCT03496883Active Not Recruiting860Est. Jan 2028
NCT07227246Recruiting350Est. Jun 2029
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Intravenous nicardipine hydrochloridePhase 31 trial
Active Trials
NCT01176565Terminated1,000Est. Mar 2016
Arrowhead Pharmaceuticals
1 program
1
StatinsPhase 31 trial
Active Trials
NCT03936361Recruiting1,456Est. Dec 2028
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
1
StatinsPhase 3
Genentech
GenentechCA - Oceanside
1 program
1
rt-PAPhase 31 trial
Active Trials
NCT01827046Completed499Est. Sep 2018
Bioxodes
BioxodesBelgium - Gosselies
1 program
1
Ir-CPIPhase 21 trial
Active Trials
NCT05970224Active Not RecruitingEst. Jul 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
NXY-059Phase 21 trial
Active Trials
NCT00075959Completed600Est. Jan 2006
Viz.ai
Viz.aiCA - San Francisco
2 programs
Viz ICH VOLUMEN/A1 trial
Viz RECRUITN/A1 trial
Active Trials
NCT04733638Completed1,000Est. Apr 2023
NCT03865979Completed10Est. Apr 2023
Penumbra
PenumbraALAMEDA, CA
1 program
Artemis Neuro Evacuation DeviceN/A1 trial
Active Trials
NCT04178746Terminated4Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Novo NordiskRecombinant Factor VIIa
Novo NordiskRecombinant Activated Factor VII
Arrowhead PharmaceuticalsStatins
Genentechrt-PA
Heidelberg PharmaIntravenous nicardipine hydrochloride
BioxodesIr-CPI
AstraZenecaNXY-059
Viz.aiViz ICH VOLUME
Viz.aiViz RECRUIT
PenumbraArtemis Neuro Evacuation Device

Clinical Trials (10)

Total enrollment: 5,779 patients across 10 trials

NCT07227246Novo NordiskRecombinant Factor VIIa

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Start: May 2025Est. completion: Jun 2029350 patients
Phase 3Recruiting
NCT03496883Novo NordiskRecombinant Activated Factor VII

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Start: Dec 2021Est. completion: Jan 2028860 patients
Phase 3Active Not Recruiting
NCT03936361Arrowhead PharmaceuticalsStatins

Statins In Intracerbral Hemorrhage

Start: Jun 2020Est. completion: Dec 20281,456 patients
Phase 3Recruiting
NCT01827046Genentechrt-PA

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Start: Dec 2013Est. completion: Sep 2018499 patients
Phase 3Completed
NCT01176565Heidelberg PharmaIntravenous nicardipine hydrochloride

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Start: May 2011Est. completion: Mar 20161,000 patients
Phase 3Terminated
NCT05970224BioxodesIr-CPI

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

Start: Nov 2023Est. completion: Jul 2027
Phase 2Active Not Recruiting
NCT00075959AstraZenecaNXY-059

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Start: Aug 2004Est. completion: Jan 2006600 patients
Phase 2Completed
NCT04733638Viz.aiViz ICH VOLUME

ADVANCE- Automated Detection and Volumetric Assessment of ICH

Start: Jan 2021Est. completion: Apr 20231,000 patients
N/ACompleted
NCT03865979Viz.aiViz RECRUIT

AI ENRICH - AI Detection of ICH

Start: Jan 2020Est. completion: Apr 202310 patients
N/ACompleted
NCT04178746PenumbraArtemis Neuro Evacuation Device

PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase

Start: Sep 2019Est. completion: Jun 20214 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 5,779 patients
9 companies competing in this space